Study guide

3.5 Integrated Case Study: Diagnosing & Remedying Prescription Drug Cost Increases

Certified Employee Benefit Specialist CEBS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: CEBS Framework & The Benefits Environment

1.1 CEBS Program Structure & Credentialing Tracks 1.2 The Employee Benefits Environment & Total Rewards Strategy 1.3 Risk Management & Financing Principles in Group Benefits

2 Chapter 2: GBA 1 — Managed Health Care & Account Mechanics

2.1 Managed Health Care Models & Plan Design 2.2 Consumer-Directed Health Plans & Account Mechanics 2.3 Section 125 Cafeteria Plans & Flexible Benefit Design

3 Chapter 3: GBA 1 — Prescription Drugs, Specialty Benefits & Wellness

3.1 Prescription Drug Benefit Design & PBM Operations 3.2 Dental, Vision, and Hearing Care Programs 3.3 Behavioral Health, EAPs & Workplace Wellness Compliance 3.4 Workplace Wellness Program Design, Incentives & Outcome Measurement 3.5 Integrated Case Study: Diagnosing & Remedying Prescription Drug Cost Increases

4 Chapter 4: GBA 1 — Health Plan Regulation & Statutory Mandates

4.1 ACA Employer Mandate & Market Reforms 4.2 COBRA Continuation Coverage Requirements & Administration 4.3 HIPAA Portability, Privacy, and Security for Group Health Plans 4.4 The No Surprises Act & Transparency in Coverage

5 Chapter 5: GBA 2 — Health Care System Dynamics & Network Design

5.1 U.S. Health Care System Dynamics & Value-Based Payment Models 5.2 Provider Network Architecture, Contracting & Reimbursement 5.3 Health Care Quality Measurement & Utilization Management 5.4 Controlling Risk Factors & Integrated Patient Care 5.5 Participant Response to Health Plan Pricing

6 Chapter 6: GBA 2 — Underwriting, Rating & Funding Strategies

6.1 Group Health Underwriting, Pricing & Rating Methodologies 6.2 Self-Funding Mechanics, Administration & Level-Funded Plans 6.3 Stop-Loss Insurance Design & Risk Transfer 6.4 Claims Lag, Reserving & Financial Underwriting Analysis 6.5 The Small-Group and Individual Insurance Market

7 Chapter 7: GBA 2 — Disability, Life & Long-Term Care Programs

7.1 Group Short-Term and Long-Term Disability Plans 7.2 Group Term Life and AD&D Insurance 7.3 Long-Term Care Insurance & Worksite Voluntary Benefits 7.4 Integrated Case Study: Employee Benefits — Balancing Competing Constraints

8 Chapter 8: GBA/RPA 3 — ERISA Statutory Framework & Plan Governance

8.1 ERISA Title I Statutory Framework & Preemption Doctrine 8.2 Plan Documentation, SPDs, SMMs & Form 5500 Reporting 8.3 Fiduciary Standards, Duties & Prohibited Transactions 8.4 ERISA in Practice: Claims Procedures, Appeals & Enforcement

9 Chapter 9: GBA/RPA 3 — Audits, Vendor Oversight & Cybersecurity

9.1 Benefit Audits, Compliance Reviews & Correction Programs 9.2 Vendor Management, RFPs, SLAs & Benefits Analytics 9.3 Cybersecurity Governance & Data Privacy for Benefit Plans 9.4 The Benefits Industry: Carriers, TPAs, Brokers & Consultants 9.5 Integrated Case Study: Preparing for & Surviving a Benefits Plan Data Breach

10 Chapter 10: GBA/RPA 3 — Social Insurance, Retiree Benefits & Global Strategy

10.1 Social Security, Medicare & Employer Plan Coordination 10.2 Retiree Health Benefit Strategies & OPEB Accounting 10.3 Global Employee Benefits & Strategic Innovation 10.4 Financial Product Innovation & Retirement Vendor Management

11 Chapter 11: RPA 1 — Qualified Plan Fundamentals & DB Pensions

11.1 Qualified Plan Foundations & Nondiscrimination Testing 11.2 Defined Benefit Pension Plan Design & Actuarial Concepts 11.3 PBGC Insurance Coverage & Plan Terminations

12 Chapter 12: RPA 1 — Defined Contribution Structures & 401(k) Plans

12.1 Core Defined Contribution Plans: Profit-Sharing & ESOPs 12.2 401(k) Plans: Elective Deferrals, Testing & Safe Harbors 12.3 Section 403(b) and 457 Deferred Compensation Plans 12.4 SECURE Act & SECURE 2.0 Modernizations 12.5 Defined Contribution Practice Issues: Forfeitures, Missing Participants, ESG & Crypto

13 Chapter 13: RPA 1 — Small Business Plans, IRAs & Executive Compensation

13.1 Small Employer Retirement Solutions: SEPs, SIMPLEs & PEPs 13.2 Individual Retirement Arrangements (IRAs) & Rollover Rules 13.3 Executive Nonqualified Deferred Compensation & IRC §409A 13.4 Stock Compensation Plans: Options, Restricted Stock, RSUs & ESPPs 13.5 Integrated Case Study: Retirement Planning — Participant Goals & Strategic Results

14 Chapter 14: RPA 2 — Capital Markets, Portfolio Theory & Asset Allocation

14.1 Capital Markets, Risk-Return Metrics & Modern Portfolio Theory 14.2 Asset Allocation Strategies, Target-Date Funds & QDIAs 14.3 Investment Vehicles: CITs, Mutual Funds & Lifetime Income 14.4 Active vs. Passive Strategies, Investment Managers & Plan Intermediaries

15 Chapter 15: RPA 2 — Behavioral Finance, Plan Operations & Investment Governance

15.1 Behavioral Finance, Choice Architecture & Financial Wellness 15.2 Hybrid Plans, Participant Loans, Hardships & RMDs 15.3 Fiduciary Investment Governance, IPS & Fee Disclosures 15.4 Plan Sponsor Administrative Responsibilities & Participant Services 15.5 Integrated Case Study: Assessing Fiduciary Concerns Under Threat of Litigation

3.5 Integrated Case Study: Diagnosing & Remedying Prescription Drug Cost Increases

Key Takeaways Explain This Topic AI

Pharmacy trend decomposes into utilization change, unit-cost change, and mix shift; the remedy depends entirely on which component is driving the increase, so decomposition must precede any plan-design change.

A double-digit pharmacy increase with flat scripts per member per year and rising cost per script points to specialty mix shift, not overutilization, and cost-sharing changes will not fix it.

Specialty drugs typically represent a low single-digit percentage of prescriptions but roughly half or more of total pharmacy spend, which is why per-script averages conceal the real driver.

Effective specialty remedies are channel and site-of-care management, prior authorization with clinical criteria, biosimilar preference, and outcomes-based contracting — not blunt copay increases, which shift cost to the sickest members and can trigger nonadherence.

Any PBM remedy must be tested against the contract: definitions of generic, brand, and specialty, rebate pass-through, spread pricing, and audit rights determine whether a negotiated 'discount improvement' produces real savings.

Last updated: September 2026

Integrated Case Study: Diagnosing & Remedying Prescription Drug Cost Increases

Quick Answer: Pharmacy cost increases are diagnosed by decomposing trend into utilization , unit cost , and mix . Flat utilization with a rising average cost per script signals a specialty mix shift , which cost-sharing changes cannot cure. The remedy set is channel and site-of-care management, prior authorization, biosimilar preference, and contract remediation with the PBM — evaluated against the plan's fiduciary duty and the members' adherence risk.

1. The Scenario

Cascadia Instruments is a 2,400-employee self-funded manufacturer, roughly 5,100 covered lives, with an integrated PBM arrangement bundled with its medical TPA. The CFO has flagged a pharmacy line that rose 18.4% year over year while medical trend held at 6.1%. The benefits committee's first instinct is to add a fourth copay tier and raise the specialty copay from $100 to $250.

The CEBS-trained analyst's first move is not to redesign anything. It is to decompose the trend.

2. Decomposing Pharmacy Trend

Pharmacy trend is the product of three factors, not a single number: Trend = ( 1 + Δ Utilization ) × ( 1 + Δ Unit Cost ) × ( 1 + Δ Mix ) − 1 \text{Trend} = (1 + \Delta\text{Utilization}) \times (1 + \Delta\text{Unit Cost}) \times (1 + \Delta\text{Mix}) - 1 Trend = ( 1 + Δ Utilization ) × ( 1 + Δ Unit Cost ) × ( 1 + Δ Mix ) − 1

Utilization — scripts per member per year (PMPY). Answers: are members filling more prescriptions?

Unit cost — net cost per script within a constant drug mix. Answers: did prices rise on the same drugs?

Mix — the distribution of scripts across generic, brand, and specialty. Answers: did the population shift toward more expensive therapies?

Cascadia's Data

  • Metric Prior Year Current Year Change
  • Scripts per member per year 11.8 11.9 +0.8%
  • Generic dispensing rate (GDR) 88.1% 89.4% +1.3 pts
  • Average net cost per script $71.40 $83.90 +17.5%
  • Specialty scripts as % of total 1.4% 2.1% +0.7 pts
  • Specialty spend as % of total 48% 57% +9 pts
  • Net plan pharmacy cost PMPM $70.20 $83.11 +18.4%

Read the evidence. Utilization is essentially flat. The generic dispensing rate improved , which normally suppresses cost. Yet cost per script rose 17.5% and specialty went from 48% to 57% of spend on 2.1% of scripts. This is a textbook mix shift , concentrated in specialty. The proposed fourth copay tier addresses none of it.

Why the Copay Increase Fails

Raising the specialty copay from $100 to $250 across roughly 107 specialty utilizers recovers on the order of $190,000 annually — under 5% of the increase — while imposing the entire burden on the sickest members. Specialty cost-sharing increases are also strongly associated with primary nonadherence (prescriptions never picked up), which for conditions such as rheumatoid arthritis or multiple sclerosis reliably converts pharmacy savings into larger medical claims. It is a cost shift , not a cost control .

3. Building the Remedy Set

Lever Mechanism Where It Bites Typical Constraint

Prior authorization & step therapy Clinical criteria before high-cost agents; require preferred agent first New specialty starts Must not violate MHPAEA NQTL parity for behavioral-health drugs; needs an expedited appeals path

Biosimilar preference Formulary places biosimilars at a preferred tier or requires them first Biologics with approved biosimilars Interchangeability and provider resistance; requires member communication

Site-of-care management Redirect infused drugs from hospital outpatient to home infusion or physician office Medical-benefit specialty drugs Requires medical-plus-pharmacy data; hospital contract terms may lock in outpatient administration

Specialty pharmacy channel Exclusive specialty network with clinical support and split-fill programs Dispensing margin and waste Narrows member choice; disruption analysis required

Outcomes-based contracts Manufacturer rebate contingent on clinical response High-cost, measurable-outcome therapies Needs data infrastructure and sufficient volume

Copay assistance coordination Structured handling of manufacturer coupons and patient assistance Member out-of-pocket Accumulator and maximizer designs raise fiduciary, ACA out-of-pocket, and state-law questions

Do not forget the medical benefit. At Cascadia, roughly 40% of specialty spend is billed under the medical benefit as physician-administered infusions and never appears in a pharmacy report at all. Any analysis built solely on PBM data will understate specialty exposure and miss the largest site-of-care opportunity.

4. Testing the PBM Contract

A negotiated "better discount" is meaningless until the contract definitions are examined. Four provisions decide whether savings are real:

Definitions of generic, brand, and specialty. If the PBM can reclassify a drug between buckets, guaranteed discount percentages can be met while total spend rises. Insist on a fixed, contractually attached specialty drug list with a change-control process.

Rebate pass-through. Distinguish "rebates" from "manufacturer administrative fees," "data fees," and "purchase discounts." A 100% rebate pass-through that excludes three other revenue categories is not transparent pricing.

Spread pricing. Under a traditional spread model the PBM bills the plan more than it reimburses the pharmacy and keeps the difference. A pass-through or transparent model eliminates spread but usually carries a higher explicit administrative fee — the comparison must be on net cost, not on the admin line.

Audit rights. The right to audit claims and rebates, using an auditor of the plan's choosing, with a workable look-back period and no unreasonable sampling limits.

5. The Recommendation

The committee's decision memo should reject the fourth copay tier as the primary remedy and instead: (1) implement prior authorization and step therapy on new specialty starts with an expedited clinical appeal; (2) adopt biosimilar-preferred placement; (3) launch site-of-care redirection for medical-benefit infusions after a combined medical-and-pharmacy data build; (4) renegotiate PBM definitions, rebate pass-through, and audit rights at the next contract window; and (5) hold member cost-sharing on specialty flat, on the documented grounds that nonadherence risk outweighs the modest recovery. Each step is recorded in committee minutes — the procedural-prudence record that a benefits fiduciary will need if the decision is later challenged.

Loading diagram... Pharmacy Trend Diagnostic Decision Tree